3 humongous healthcare stocks this week 3-21-14

8,791 views
8,690 views

Published on

The biggest healthcare stocks of the week

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
8,791
On SlideShare
0
From Embeds
0
Number of Embeds
8,082
Actions
Shares
0
Downloads
11
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • 3 humongous healthcare stocks this week 3-21-14

    1. 1. 3 Humongous Health-Care Stocks This Week
    2. 2. March Madness isn’t just sweeping the basketball world by storm. It’s not the Final Four, but here are your top three humongous health-care stocks. Source: Wikimedia Commons
    3. 3. Shares of the biotech soared 106% this week. Endocyte (Nasdaq: ECYT) $- $0.50 $1.00 $1.50 $2.00 $2.50 $3.00 3/14/14 3/17/14 3/18/14 3/19/14 3/20/14 3/21/14 ECYT Stock Performance Source: Yahoo! Finance
    4. 4. • Europe’s Committee for Medicinal Products for Human Use gave positive recommendations for ovarian cancer drug Vynfinit and companion imaging components. • Vynfinit combined with docetaxel met its primary endpoint in a phase 2b study targeting treatment of non-small-cell lung cancer. • Piper Jaffray immediately raised its price target for Endocyte from $17 to $36. Why Endocyte exploded
    5. 5. Shares of the specialty pharmaceutical company surged nearly 32% this week. Horizon Pharma (Nasdaq: HZNP) $- $0.50 $1.00 $1.50 $2.00 $2.50 $3.00 3/14/14 3/17/14 3/18/14 3/19/14 3/20/14 3/21/14 HZNP Stock Performance Source: Yahoo! Finance
    6. 6. • It announced a $660 million reverse merger deal with privately held Vidara Therapeutics. • Vidara markets ACTIMMUNE for treating chronic granulomatous disease and severe, malignant osteoporosis. • The combined company is expected to generate $250 million to $265 million in revenue in 2014. Why Horizon Pharma soared
    7. 7. Shares of the biopharmaceutical company jumped almost 21% higher for the week. Geron (Nasdaq: GERN) $- $0.50 $1.00 $1.50 $2.00 $2.50 $3.00 3/14/14 3/17/14 3/18/14 3/19/14 3/20/14 3/21/14 GERN Stock Performance Source: Yahoo! Finance
    8. 8. • The stock got hammered last week following Geron’s announcement that the FDA placed a full clinical hold on am Investigational New Drug application for imetelstat because of liver test abnormalities in a phase 2 study. • Shares jumped 40% higher early this week, perhaps because some investors thought the worst news was behind Geron. • The stock gave back many of those gains later in the week, though, partially as a result of Geron’s announcement of a partial clinical hold on a Mayo Clinic study of imetelstat. Why Geron bounced
    9. 9. • Endocyte appears to be the best choice out of this week’s humongous winners. • At least one analyst, Brean Capital’s Gene Mack, thinks Vynfinit has the potential to eventually hit peak sales of $2 billion if all indications are ultimately approved. • Horizon Pharma could continue to do well over the long run, especially if it achieves synergies from the Vidara merger. • Geron is a riskier bet, but I wouldn’t rule out the potential for imetelstat. Best pick to stay humongous?
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!

    ×